| Cat.No. | Name | Information |
|---|---|---|
| M1825 | PCI-32765 | PCI-32765 (Ibrutinib) is a potent, selective and orally bioavailable irreversible inhibitor of BTK with IC50 value of 0.46 nM. |
| M25403 | NX-2127 | NX-2127 is an orally bioavailable BTK degrader with immunomodulatory activity, used for the research of recurrent or refractory B-cell malignancies. |
| M14880 | BMX-IN-1 | BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys496 in the BMX ATP binding domain with an IC50 of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity. |
| M14879 | (±)-Zanubrutinib | (±)-Zanubrutinib ((±)-BGB-3111) is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor. |
| M10605 | Rilzabrutinib | Rilzabrutinib, also known as PRN1008, is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK) with IC50 of 1.3 nM. |
| M10604 | Pirtobrutinib (LOXO-305) | Pirtobrutinib (LOXO-305; LY 3527727; RXC-005) is a highly selective and non-covalent next generation BTK inhibitor, which inhibits diverse BTK C481 substitution mutations. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases. |
| M10500 | Remibrutinib (LOU064) | Remibrutinib (LOU064) is a potentially best-in-class "best-in-class" orally active bruton tyrosine kinase (BTK) inhibitor with an IC50 value of 1 nM and an IC50 value of 0.23 μM for inhibition of BTK activity in blood. Remibrutinib can be used to study chronic urticaria (CU). |
| M10274 | Tolebrutinib | Tolebrutinib (SAR442168) is a potent, selective, orally active and blood-brain barrier capable bruton's tyrosine kinase (BTK) inhibitor with IC50 values of 0.4 and 0.7 nM in Ramos B cells and HMC microglia, respectively. Tolebrutinib has an effect on central nervous system immunity. Tolebrutinib can be used in multiple sclerosis (MS) studies. |
| M10095 | Orelabrutinib | Orelabrutinib is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK). |
| M10025 | Zanubrutinib | Zanubrutinib (BGB-3111) is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). |
| M9958 | ARQ 531 | ARQ 531 is a potent reversible inhibitor of BTK (IC50 = 0.85 nM), exhibits potent antitumor activity in ibrutinib-resistant diffuse large B-cell lymphoma. |
| M9889 | PCI-29732 | PCI-29732 is a potent, reversible BTK inhibitor. |
| M9628 | Branebrutinib | Branebrutinib (BMS-986195) is a potent, covalent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK), with IC50 of 0.1 nM. |
| M9257 | Evobrutinib | Evobrutinib is an oral, potent, and highly selective, covalent Bruton's Tyrosine Kinase (BTK) inhibitor with an IC50 of 37.9 nM. |
| M9166 | BMS-986142 | BMS-986142 is a potent, selective, reversible BTK inhibitor, shows BTK IC50 = 0.5nM; human WB IC50 = 90 nM. |
| M8941 | GDC-0853 (Fenebrutinib) | GDC-0853 (Fenebrutinib) is a potent, selective and non-covalent bruton tyrosine kinase (Btk) inhibitor with a Ki value of 0.91 nM against BRK. |
| M8887 | Btk inhibitor 2 | Btk inhibitor 2 (BGB-3111) is a Brutons tyrosine kinase (BTK) inhibitor. |
| M7536 | BMS-935177 | BMS-935177 is a potent, reversible Bruton's Tyrosine Kinase (BTK) inhibitor with an IC50 value of 2.8 nM and demonstrates good kinase selectivity. It is more potent against BTK than other kinase, including the other Tec family kinases (TEC, BMX, ITK, and TXK) over which the compound is between 5- and 67-fold selective. |
| M6907 | LFM-A13 | LFM-A13 is a specific Bruton's tyrosine kinase (BTK) inhibitor with IC50 of 2.5 μM. |
| M6636 | CTA 056 | CTA 056 is a iTK inhibitor. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
